Published: October 13, 2026
Nutraceuticals World reports that Maypro has signed an exclusive agreement with Waleria Healthtech to distribute Aspurus, a full-spectrum shatavari root extract, in the United States.
The ingredient adds to Maypro’s women’s health portfolio and is positioned to support women through their reproductive years, perimenopause and menopause.
Aspurus is characterized for seven naturally occurring shatavarins and standardized to 5% total shatavarins, with the aim of preserving the root’s broader phytochemical profile.
A randomized, double-blind, placebo-controlled study in the Journal of Dietary Supplements gave 150 women aged 35 to 55 a daily 500 mg dose for 12 weeks. Participants saw improvements in vasomotor symptoms, cognition, anxiety, fatigue and other perimenopause measures.
The article includes comments from Maypro CEO May Yamada-Lifton, Maypro’s Lauren Clardy and Waleria founder Komal Baldwa.
